Title |
PSA screening for prostate cancer
|
---|---|
Published in |
Revista da Associação Médica Brasileira, August 2017
|
DOI | 10.1590/1806-9282.63.08.722 |
Pubmed ID | |
Authors |
Marcus V. Sadi |
Abstract |
Screening of prostate cancer with prostate-specific antigen (PSA) is a highly controversial issue. One part of the controversy is due to the confusion between population screening and early diagnosis, another derives from problems related to the quality of existing screening studies, the results of radical curative treatment for low grade tumors and the complications resulting from treatments that affect the patient's quality of life. Our review aimed to critically analyze the current recommendations for PSA testing, based on new data provided by the re-evaluation of the ongoing studies and the updated USPSTF recommendation statement, and to propose a more rational and selective use of PSA compared with baseline values obtained at an approximate age of 40 to 50 years. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 104 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 16 | 15% |
Student > Master | 15 | 14% |
Researcher | 10 | 10% |
Student > Postgraduate | 8 | 8% |
Other | 7 | 7% |
Other | 21 | 20% |
Unknown | 27 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 31 | 30% |
Biochemistry, Genetics and Molecular Biology | 13 | 13% |
Nursing and Health Professions | 11 | 11% |
Unspecified | 4 | 4% |
Agricultural and Biological Sciences | 3 | 3% |
Other | 12 | 12% |
Unknown | 30 | 29% |